董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hugh Griffith | 男 | Chief Executive Officer and Director | 57 | 109.12万 | 282996.19 | 2026-06-01 |
| Cyrille Leperlier | 男 | Non-Executive Director | 72 | 4.62万 | 7228.99 | 2026-06-01 |
| Andrew Kay | 男 | Chairman and Non-Executive Director | 70 | 7.38万 | 11658.21 | 2026-06-01 |
| Elliott Levy | 男 | Non-Executive Director | 67 | 3.89万 | 5246.22 | 2026-06-01 |
| Martin Mellish | 男 | Non-Executive Director | 68 | 5.16万 | 7763.07 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hugh Griffith | 男 | Chief Executive Officer and Director | 57 | 109.12万 | 282996.19 | 2026-06-01 |
| Jeffrey Bloss | 男 | Chief Medical Officer | 69 | 未披露 | 16099.76 | 2026-06-01 |
| David Harrison | 男 | Head of Translational Medicine | 66 | 未披露 | 14199.21 | 2026-06-01 |
| Theresa Bruce | 女 | Chief Operating Officer | 61 | 未披露 | 5513.96 | 2026-06-01 |
| Ian Webster | 男 | Chief Financial Officer | 45 | 未披露 | 13115.48 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- Hugh Griffith
-
Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
Hugh Griffith is co founder and has served as Chief Executive Officer and as a member of board of directors since operations began in March 2008. Mr. Griffith previoly served as a non executive director of MedAnnex Limited from 2010 to 2024, Thirty Holdings Limited from 2018 to 2023 and EdixoMed Limited from 2011 to 2023, when it was acquired by Convatec Group. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007, when it was acquired by Genzyme Corporation (now Sanofi). He previoly served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002, Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018, Mr. Griffith received a lifetime achievement award for 'Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Biness School and a B.Sc. Hons in Biology from the University of Stirling. - Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
- Hugh Griffith is co founder and has served as Chief Executive Officer and as a member of board of directors since operations began in March 2008. Mr. Griffith previoly served as a non executive director of MedAnnex Limited from 2010 to 2024, Thirty Holdings Limited from 2018 to 2023 and EdixoMed Limited from 2011 to 2023, when it was acquired by Convatec Group. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007, when it was acquired by Genzyme Corporation (now Sanofi). He previoly served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002, Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018, Mr. Griffith received a lifetime achievement award for 'Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Biness School and a B.Sc. Hons in Biology from the University of Stirling.
- Cyrille Leperlier
-
Cyrille Leperlier自2018年5月以来一直担任我们的董事会成员。最近，他曾担任Sanofi公司的企业业务发展和并购集团的高级科学顾问，在那里，除其他交易外，他曾深入参与Sanofi公司收购Genzyme公司。在此之前，Leperlier博士担任Sanofi在日本的医疗总监，在加入Sanofi之前，Leperlier博士是Rhone Poulenc Rorer的医疗总监兼临床开发全球主管，之前曾在Takeda担任各种运营和医疗事务角色。Leperlier博士在巴黎大学圣安东尼医学院（University of Paris，Saint-Antoine School of Medicine）获得医学博士学位，并在巴黎医科大学（Medical University of Paris）获得生理学人类生物学硕士学位。他是公认的肿瘤药物开发、战略投资组合优先排序和业务发展专家，在多家全球生物技术和制药公司拥有丰富的领导经验。
Cyrille Leperlier has served as a member of board of directors since May 2018. Dr. Leperlier also served as the Chief Executive Officer of Divlal SAS from June 2020 to November 2022. From 2009 to 2019, Dr. Leperlier also served as Vice President of Medical Assessment for Corporate Strategy for Sanofi's Corporate Biness Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi's acquisition of Genzyme. Prior to this role, Dr. Leperlier served at Sanofi as Medical Director in Japan from 2007 to 2009 and Head of Medical Affairs, International Region from 2004 to 2007. Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previoly worked for Takeda in a variety of operational and medical affairs roles. Dr. Leperlier received an M.D. from the University of Paris, Saint Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris. He is a recognized expert in oncology drug development, strategic portfolio prioritization, and biness development, with extensive leadership experience at a number of global biotechnology and pharmaceutical companies. - Cyrille Leperlier自2018年5月以来一直担任我们的董事会成员。最近，他曾担任Sanofi公司的企业业务发展和并购集团的高级科学顾问，在那里，除其他交易外，他曾深入参与Sanofi公司收购Genzyme公司。在此之前，Leperlier博士担任Sanofi在日本的医疗总监，在加入Sanofi之前，Leperlier博士是Rhone Poulenc Rorer的医疗总监兼临床开发全球主管，之前曾在Takeda担任各种运营和医疗事务角色。Leperlier博士在巴黎大学圣安东尼医学院（University of Paris，Saint-Antoine School of Medicine）获得医学博士学位，并在巴黎医科大学（Medical University of Paris）获得生理学人类生物学硕士学位。他是公认的肿瘤药物开发、战略投资组合优先排序和业务发展专家，在多家全球生物技术和制药公司拥有丰富的领导经验。
- Cyrille Leperlier has served as a member of board of directors since May 2018. Dr. Leperlier also served as the Chief Executive Officer of Divlal SAS from June 2020 to November 2022. From 2009 to 2019, Dr. Leperlier also served as Vice President of Medical Assessment for Corporate Strategy for Sanofi's Corporate Biness Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi's acquisition of Genzyme. Prior to this role, Dr. Leperlier served at Sanofi as Medical Director in Japan from 2007 to 2009 and Head of Medical Affairs, International Region from 2004 to 2007. Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previoly worked for Takeda in a variety of operational and medical affairs roles. Dr. Leperlier received an M.D. from the University of Paris, Saint Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris. He is a recognized expert in oncology drug development, strategic portfolio prioritization, and biness development, with extensive leadership experience at a number of global biotechnology and pharmaceutical companies.
- Andrew Kay
-
Andrew Kay自2020年12月起担任我们的董事会主席。Kay先生自2017年9月起担任Nerre Therapeutics董事会主席，自2015年8月起担任Blueberry Therapeutics董事会主席。从2019年1月到2020年9月，他担任Kandy Therapeutics的相同职位，该公司是一家被Bayer收购的生物技术公司。2015年9月至2018年6月，Kay先生担任Wilson Therapeutics（生物制药公司，于2018年被Alexion Pharmaceuticals收购）的董事会主席。在此之前，Kay先生从2009年1月到2014年5月担任Algeta的总裁兼首席执行官。加入Algeta之前，Kay先生曾担任Novartis的市场营销与销售全球主管、医疗保健委员会和制药执行委员会的成员（从1999年到2003年），并在欧洲和美国担任过其他几个高级商业职位，曾任职Renovo，阿斯利康，Eli Lilly，山德士和靴子。凯先生在诺丁汉大学获得了药学荣誉学士学位。我们认为，Kay先生具有特定的特质，有资格担任我们董事会的成员，包括他在生物技术和制药公司的丰富经验。
Andrew Kay has served as Chairman of board of directors since December 2020 and served as Executive Chairman of board from June 2025 to December 2025. Mr. Kay has served as Chairman of the Board of NeRRe Therapeutics since September 2017, as Chairman of WalkSafe Chaperhome Limited since March 2021, as Chairman and director of Amulet Consulting since 2014, and as Chairman of AdvanCell Brisbane since October 2025. Mr. Kay served as Chairman of the Board of Blueberry Therapeutics from August 2015 to October 2023. From January 2019 to September 2020, he held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer. From September 2015 to June 2018, Mr. Kay served as Chairman of the Board of Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals in 2018. Prior to that, Mr. Kay served as the President and Chief Executive Officer for Algeta from January 2009 to May 2014. Prior to Algeta, Mr. Kay was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis 1999 to 2003, and held several other senior commercial positions in Europe and the United States having worked at Renovo, AstraZeneca, Eli Lilly, Sandoz and Boots. Mr. Kay earned his Bachelor of Honors in Pharmacy from Nottingham University. - Andrew Kay自2020年12月起担任我们的董事会主席。Kay先生自2017年9月起担任Nerre Therapeutics董事会主席，自2015年8月起担任Blueberry Therapeutics董事会主席。从2019年1月到2020年9月，他担任Kandy Therapeutics的相同职位，该公司是一家被Bayer收购的生物技术公司。2015年9月至2018年6月，Kay先生担任Wilson Therapeutics（生物制药公司，于2018年被Alexion Pharmaceuticals收购）的董事会主席。在此之前，Kay先生从2009年1月到2014年5月担任Algeta的总裁兼首席执行官。加入Algeta之前，Kay先生曾担任Novartis的市场营销与销售全球主管、医疗保健委员会和制药执行委员会的成员（从1999年到2003年），并在欧洲和美国担任过其他几个高级商业职位，曾任职Renovo，阿斯利康，Eli Lilly，山德士和靴子。凯先生在诺丁汉大学获得了药学荣誉学士学位。我们认为，Kay先生具有特定的特质，有资格担任我们董事会的成员，包括他在生物技术和制药公司的丰富经验。
- Andrew Kay has served as Chairman of board of directors since December 2020 and served as Executive Chairman of board from June 2025 to December 2025. Mr. Kay has served as Chairman of the Board of NeRRe Therapeutics since September 2017, as Chairman of WalkSafe Chaperhome Limited since March 2021, as Chairman and director of Amulet Consulting since 2014, and as Chairman of AdvanCell Brisbane since October 2025. Mr. Kay served as Chairman of the Board of Blueberry Therapeutics from August 2015 to October 2023. From January 2019 to September 2020, he held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer. From September 2015 to June 2018, Mr. Kay served as Chairman of the Board of Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals in 2018. Prior to that, Mr. Kay served as the President and Chief Executive Officer for Algeta from January 2009 to May 2014. Prior to Algeta, Mr. Kay was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis 1999 to 2003, and held several other senior commercial positions in Europe and the United States having worked at Renovo, AstraZeneca, Eli Lilly, Sandoz and Boots. Mr. Kay earned his Bachelor of Honors in Pharmacy from Nottingham University.
- Elliott Levy
-
Elliott Levy自2021年11月起担任董事会成员。Levy博士自2021年5月起担任波士顿咨询公司的高级顾问，自2022年4月起担任5AM Ventures的风险合伙人。Levy博士于2020年6月至2021年5月期间担任生物技术公司安进公司的研发、战略和运营高级副总裁。在2020年6月之前，Levy博士还是安进公司全球发展高级副总裁。Levy博士曾担任Intrepid Alliance，Inc.的负责人，该公司是一家非营利组织，其目标是促进未来大流行代理的小分子疗法的开发，并担任Transcelerate Biopharma，Inc的董事和董事会主席，该非营利组织专注于改进和加速新疗法的开发。此外，Levy博士目前还担任Omega Therapeutics、Editas Medicines（NASDAQ：EDIT）和Kinaset Therapeutics的董事。Levy博士在生物制药行业研究药物的临床开发和监管批准方面拥有24年的经验。Levy博士拥有耶鲁大学医学院的医学博士学位和耶鲁大学的历史学学士学位。
Elliott Levy has served as a member of board of directors since November 2021. Dr. Levy has served as a Senior Advisor at Boston Consulting Group since May 2021 and as a Venture Partner at 5AM Ventures since April 2022. Dr. Levy was Senior Vice President of Research & Development, Strategy and Operations of Amgen Inc., a biotechnology firm from June 2020 to May 2021. Prior to June 2020, Dr. Levy was also Senior Vice President of Global Development at Amgen Inc. Dr. Levy has served as the Head of Intrepid Alliance, Inc., a non profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents, and as a director and Board Chair of Transcelerate Biopharma, Inc, a non profit focused on improving and accelerating the development of new therapeutics. Further, Dr. Levy currently serves as a director of Omega Therapeutics, Editas Medicines (NASDAQ: EDIT) and Kinaset Therapeutics. Dr. Levy has 24 years' experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. Dr. Levy holds an M.D. from the Yale School of Medicine and a B.A. in History from Yale College. - Elliott Levy自2021年11月起担任董事会成员。Levy博士自2021年5月起担任波士顿咨询公司的高级顾问，自2022年4月起担任5AM Ventures的风险合伙人。Levy博士于2020年6月至2021年5月期间担任生物技术公司安进公司的研发、战略和运营高级副总裁。在2020年6月之前，Levy博士还是安进公司全球发展高级副总裁。Levy博士曾担任Intrepid Alliance，Inc.的负责人，该公司是一家非营利组织，其目标是促进未来大流行代理的小分子疗法的开发，并担任Transcelerate Biopharma，Inc的董事和董事会主席，该非营利组织专注于改进和加速新疗法的开发。此外，Levy博士目前还担任Omega Therapeutics、Editas Medicines（NASDAQ：EDIT）和Kinaset Therapeutics的董事。Levy博士在生物制药行业研究药物的临床开发和监管批准方面拥有24年的经验。Levy博士拥有耶鲁大学医学院的医学博士学位和耶鲁大学的历史学学士学位。
- Elliott Levy has served as a member of board of directors since November 2021. Dr. Levy has served as a Senior Advisor at Boston Consulting Group since May 2021 and as a Venture Partner at 5AM Ventures since April 2022. Dr. Levy was Senior Vice President of Research & Development, Strategy and Operations of Amgen Inc., a biotechnology firm from June 2020 to May 2021. Prior to June 2020, Dr. Levy was also Senior Vice President of Global Development at Amgen Inc. Dr. Levy has served as the Head of Intrepid Alliance, Inc., a non profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents, and as a director and Board Chair of Transcelerate Biopharma, Inc, a non profit focused on improving and accelerating the development of new therapeutics. Further, Dr. Levy currently serves as a director of Omega Therapeutics, Editas Medicines (NASDAQ: EDIT) and Kinaset Therapeutics. Dr. Levy has 24 years' experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. Dr. Levy holds an M.D. from the Yale School of Medicine and a B.A. in History from Yale College.
- Martin Mellish
-
Martin Mellish曾担任Aspen Advisory Services Ltd.的董事长，该公司是一家总部位于伦敦的私人办公室，负责监督在北美、欧洲和亚洲的投资。Mellish先生担任非执行董事并担任审计委员会主席：Nucana Ltd（NASD：NCNA）是一家发展阶段的生物技术公司，Pearl Diver Credit Company Inc（NYSE：PDCC）是一家封闭式注册投资公司，Alturki Holding是一家沙特阿拉伯工业投资公司，Levitronix Technologies Inc.是一家服务于半导体和生命科学行业的技术公司，以及其他非执行董事职务。他是波士顿马萨诸塞州布里格姆将军（MGB）国际顾问委员会的成员。他拥有达特茅斯医疗保健提供科学硕士项目的理学硕士学位；麻省理工学院的SM（管理学）和理学硕士学位。东北大学（会计学）。
Martin Mellish has served as chairman of Aspen Advisory Services Ltd. a London based private office overseeing investments in North America, Europe, and Asia. Mr. Mellish serves as non executive director chairs the audit committees of: Nucana Ltd (NASD:NCNA) a development stage biotechnology company, Pearl Diver Credit Company Inc (NYSE:PDCC) a closed end registered investment company, Alturki Holding, a Saudi Arabian industrial investment company, and Levitronix Technologies Inc., a technology company serving the semiconductor and life science industries, among other non executive directorships. He is a member of the International Advisory Council of Massachusetts General Brigham (MGB), Boston. He holds an M.Sc. from the Master of Health Care Delivery Science program at Dartmouth; an SM (Management) from the Massachusetts Institute of Technology and an M.Sc. (Accounting) from Northeastern University. - Martin Mellish曾担任Aspen Advisory Services Ltd.的董事长，该公司是一家总部位于伦敦的私人办公室，负责监督在北美、欧洲和亚洲的投资。Mellish先生担任非执行董事并担任审计委员会主席：Nucana Ltd（NASD：NCNA）是一家发展阶段的生物技术公司，Pearl Diver Credit Company Inc（NYSE：PDCC）是一家封闭式注册投资公司，Alturki Holding是一家沙特阿拉伯工业投资公司，Levitronix Technologies Inc.是一家服务于半导体和生命科学行业的技术公司，以及其他非执行董事职务。他是波士顿马萨诸塞州布里格姆将军（MGB）国际顾问委员会的成员。他拥有达特茅斯医疗保健提供科学硕士项目的理学硕士学位；麻省理工学院的SM（管理学）和理学硕士学位。东北大学（会计学）。
- Martin Mellish has served as chairman of Aspen Advisory Services Ltd. a London based private office overseeing investments in North America, Europe, and Asia. Mr. Mellish serves as non executive director chairs the audit committees of: Nucana Ltd (NASD:NCNA) a development stage biotechnology company, Pearl Diver Credit Company Inc (NYSE:PDCC) a closed end registered investment company, Alturki Holding, a Saudi Arabian industrial investment company, and Levitronix Technologies Inc., a technology company serving the semiconductor and life science industries, among other non executive directorships. He is a member of the International Advisory Council of Massachusetts General Brigham (MGB), Boston. He holds an M.Sc. from the Master of Health Care Delivery Science program at Dartmouth; an SM (Management) from the Massachusetts Institute of Technology and an M.Sc. (Accounting) from Northeastern University.
高管简历
中英对照 | 中文 | 英文- Hugh Griffith
Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
Hugh Griffith is co founder and has served as Chief Executive Officer and as a member of board of directors since operations began in March 2008. Mr. Griffith previoly served as a non executive director of MedAnnex Limited from 2010 to 2024, Thirty Holdings Limited from 2018 to 2023 and EdixoMed Limited from 2011 to 2023, when it was acquired by Convatec Group. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007, when it was acquired by Genzyme Corporation (now Sanofi). He previoly served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002, Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018, Mr. Griffith received a lifetime achievement award for 'Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Biness School and a B.Sc. Hons in Biology from the University of Stirling.- Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
- Hugh Griffith is co founder and has served as Chief Executive Officer and as a member of board of directors since operations began in March 2008. Mr. Griffith previoly served as a non executive director of MedAnnex Limited from 2010 to 2024, Thirty Holdings Limited from 2018 to 2023 and EdixoMed Limited from 2011 to 2023, when it was acquired by Convatec Group. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007, when it was acquired by Genzyme Corporation (now Sanofi). He previoly served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002, Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018, Mr. Griffith received a lifetime achievement award for 'Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Biness School and a B.Sc. Hons in Biology from the University of Stirling.
- Jeffrey Bloss
Jeffrey Bloss，自2021年8月起担任我们的首席医疗官。此外，他在多家生物制药公司拥有超过20年的肿瘤学领导经验。在加入NuCana之前，Bloss博士于2018年8月至2021年8月担任风险投资支持的临床阶段肿瘤公司Tarveda Therapuetics的首席医疗官。在加入Tarveda之前，Bloss博士于2017年6月至2018年8月担任Aegerion Pharmaceuticals的首席医疗官兼医疗事务高级副总裁。Bloss博士在美国空军威尔福德霍尔医学中心完成了妇产科住院医师培训，并在加州大学欧文分校完成了妇科肿瘤学奖学金。Bloss博士获得了托马斯杰斐逊大学医学院的医学博士学位和理学学士学位。来自朱尼亚塔学院。
Jeffrey Bloss has served as Chief Medical Officer since August 2021. In addition, he has over 20 years of leadership experience in oncology at multiple pharmaceutical/biopharmaceutical companies including Eli Lilly, Genentech, Xencor, GSK, Astellas, and Aegerion. Immediately prior to joining NuCana, Dr. Bloss served as Chief Medical Officer of Tarveda Therapeutics a venture backed clinical stage oncology company from August 2018 to August 2021. Prior to Tarveda, Dr. Bloss was Chief Medical Officer and Senior Vice President, Medical Affairs at Aegerion Pharmaceuticals from June 2017 to August 2018. Dr. Bloss completed his Residency in Obstetrics & Gynecology at Wilford Hall AF Medical Center and his Fellowship in Gynecologic Oncology at the University of California, Irvine. Dr. Bloss received his M.D. from Thomas Jefferson University Medical College and B.S. from Juniata College.- Jeffrey Bloss，自2021年8月起担任我们的首席医疗官。此外，他在多家生物制药公司拥有超过20年的肿瘤学领导经验。在加入NuCana之前，Bloss博士于2018年8月至2021年8月担任风险投资支持的临床阶段肿瘤公司Tarveda Therapuetics的首席医疗官。在加入Tarveda之前，Bloss博士于2017年6月至2018年8月担任Aegerion Pharmaceuticals的首席医疗官兼医疗事务高级副总裁。Bloss博士在美国空军威尔福德霍尔医学中心完成了妇产科住院医师培训，并在加州大学欧文分校完成了妇科肿瘤学奖学金。Bloss博士获得了托马斯杰斐逊大学医学院的医学博士学位和理学学士学位。来自朱尼亚塔学院。
- Jeffrey Bloss has served as Chief Medical Officer since August 2021. In addition, he has over 20 years of leadership experience in oncology at multiple pharmaceutical/biopharmaceutical companies including Eli Lilly, Genentech, Xencor, GSK, Astellas, and Aegerion. Immediately prior to joining NuCana, Dr. Bloss served as Chief Medical Officer of Tarveda Therapeutics a venture backed clinical stage oncology company from August 2018 to August 2021. Prior to Tarveda, Dr. Bloss was Chief Medical Officer and Senior Vice President, Medical Affairs at Aegerion Pharmaceuticals from June 2017 to August 2018. Dr. Bloss completed his Residency in Obstetrics & Gynecology at Wilford Hall AF Medical Center and his Fellowship in Gynecologic Oncology at the University of California, Irvine. Dr. Bloss received his M.D. from Thomas Jefferson University Medical College and B.S. from Juniata College.
- David Harrison
David Harrison，自2017年12月起担任转化医学负责人。哈里森博士自2012年5月起担任圣安德鲁斯大学病理学教授、爱丁堡大学名誉教授，并自2003年起担任佛罗里达大学兼职教授。他还在爱丁堡的洛锡安NHS大学医院监督与使用人体组织相关的伦理道德，他是该医院的名誉病理学家顾问。哈里森博士自2015年5月起担任英国政府委员会致癌性咨询委员会主席，他是致突变性委员会成员。2019年2月至2023年5月，Harrison博士成立并指导了iCAIRD，这是一项由政府和行业资助的计划，旨在促进将人工智能应用于数字诊断的研发。Harrison博士此前曾于2014年4月至2025年5月担任Benenox Limited的董事。此外，哈里森博士是ILC Therapeutics Limited的非执行董事。哈里森博士是伦敦皇家病理学家学院、爱丁堡皇家内科医学院和爱丁堡皇家外科医学院的院士。他在爱丁堡大学接受了医学和医学博士培训。
David Harrison,has served as Head of Translational Medicine since December 2017. Dr. Harrison is also professor of Pathology at the University of St. Andrews since May 2012, honorary professor at The University of Edinburgh, and an adjunct professor at the University of Florida since 2003. He also oversees ethics relating to use of human tissue at Lothian NHS University Hospitals in Edinburgh where he is an honorary consultant pathologist. Dr. Harrison has served as Chair of the U.K. Government advisory Committee on Committee Carcinogenicity since May 2015, and he is a member of the Committee on Mutagenicity. From February 2019 to May 2023, Dr. Harrison established and directed iCAIRD, a government and industry funded initiative to facilitate research and development applying artificial intelligence in digital diagnostics and Dr. Harrison previously served as a director of Benenox Limited from April 2014 to May 2025. Further, Dr. Harrison is a non-executive director at ILC Therapeutics Limited. Dr. Harrison is a Fellow of the Royal College of Pathologists, London, Royal College of Physicians of Edinburgh, and Royal College of Surgeons of Edinburgh. He received his medical and M.D. doctoral training at the University of Edinburgh.- David Harrison，自2017年12月起担任转化医学负责人。哈里森博士自2012年5月起担任圣安德鲁斯大学病理学教授、爱丁堡大学名誉教授，并自2003年起担任佛罗里达大学兼职教授。他还在爱丁堡的洛锡安NHS大学医院监督与使用人体组织相关的伦理道德，他是该医院的名誉病理学家顾问。哈里森博士自2015年5月起担任英国政府委员会致癌性咨询委员会主席，他是致突变性委员会成员。2019年2月至2023年5月，Harrison博士成立并指导了iCAIRD，这是一项由政府和行业资助的计划，旨在促进将人工智能应用于数字诊断的研发。Harrison博士此前曾于2014年4月至2025年5月担任Benenox Limited的董事。此外，哈里森博士是ILC Therapeutics Limited的非执行董事。哈里森博士是伦敦皇家病理学家学院、爱丁堡皇家内科医学院和爱丁堡皇家外科医学院的院士。他在爱丁堡大学接受了医学和医学博士培训。
- David Harrison,has served as Head of Translational Medicine since December 2017. Dr. Harrison is also professor of Pathology at the University of St. Andrews since May 2012, honorary professor at The University of Edinburgh, and an adjunct professor at the University of Florida since 2003. He also oversees ethics relating to use of human tissue at Lothian NHS University Hospitals in Edinburgh where he is an honorary consultant pathologist. Dr. Harrison has served as Chair of the U.K. Government advisory Committee on Committee Carcinogenicity since May 2015, and he is a member of the Committee on Mutagenicity. From February 2019 to May 2023, Dr. Harrison established and directed iCAIRD, a government and industry funded initiative to facilitate research and development applying artificial intelligence in digital diagnostics and Dr. Harrison previously served as a director of Benenox Limited from April 2014 to May 2025. Further, Dr. Harrison is a non-executive director at ILC Therapeutics Limited. Dr. Harrison is a Fellow of the Royal College of Pathologists, London, Royal College of Physicians of Edinburgh, and Royal College of Surgeons of Edinburgh. He received his medical and M.D. doctoral training at the University of Edinburgh.
- Theresa Bruce
特蕾莎布鲁斯，自2026年1月起担任公司首席运营官，此前自2018年起担任临床运营高级副总裁。Bruce女士在肿瘤学研发方面拥有超过25年的经验，她曾在肿瘤学、血液学和内分泌学治疗领域的临床规划和交付的各个方面领导团队。Bruce女士曾担任Nexus Oncology的首席运营官，Bruce女士曾在临床研究组织和生物技术公司担任高管职务，包括在Chiltern、Veristat的临床运营高级副总裁，最近还在NUCana任职。在加入我们之前，Bruce女士曾担任美国生物技术公司的独立顾问，负责在北美以外地区扩展临床试验组合。Bruce女士拥有格拉斯哥喀里多尼亚大学的工商管理硕士学位，在那里她专注于行政领导和战略管理，并且是特许管理协会的成员。
Theresa Bruce,has served as the company's Chief Operating Officer since January 2026 and previously served as Senior Vice President of Clinical Operations since 2018. Ms. Bruce has over 25 years of experience in oncology research and development where she has led teams in all aspects of clinical planning and delivery across oncology, hematology, and endocrinology therapeutic areas. Ms. Bruce was formerly the Chief Operating Officer at Nexus Oncology, and Ms. Bruce has held executive positions in both clinical research organizations and biotechnology companies, including SVP Clinical Operations at Chiltern, Veristat, and more recently at NuCana. Prior to joining us, Ms. Bruce worked as an independent consultant to U.S. biotech companies where she was responsible for expanding clinical trial portfolios outside of North America. Ms. Bruce holds an M.B.A. from Glasgow Caledonian University where she focused in Executive Leadership and Strategic Management, and is a Member of the Chartered Management Institute.- 特蕾莎布鲁斯，自2026年1月起担任公司首席运营官，此前自2018年起担任临床运营高级副总裁。Bruce女士在肿瘤学研发方面拥有超过25年的经验，她曾在肿瘤学、血液学和内分泌学治疗领域的临床规划和交付的各个方面领导团队。Bruce女士曾担任Nexus Oncology的首席运营官，Bruce女士曾在临床研究组织和生物技术公司担任高管职务，包括在Chiltern、Veristat的临床运营高级副总裁，最近还在NUCana任职。在加入我们之前，Bruce女士曾担任美国生物技术公司的独立顾问，负责在北美以外地区扩展临床试验组合。Bruce女士拥有格拉斯哥喀里多尼亚大学的工商管理硕士学位，在那里她专注于行政领导和战略管理，并且是特许管理协会的成员。
- Theresa Bruce,has served as the company's Chief Operating Officer since January 2026 and previously served as Senior Vice President of Clinical Operations since 2018. Ms. Bruce has over 25 years of experience in oncology research and development where she has led teams in all aspects of clinical planning and delivery across oncology, hematology, and endocrinology therapeutic areas. Ms. Bruce was formerly the Chief Operating Officer at Nexus Oncology, and Ms. Bruce has held executive positions in both clinical research organizations and biotechnology companies, including SVP Clinical Operations at Chiltern, Veristat, and more recently at NuCana. Prior to joining us, Ms. Bruce worked as an independent consultant to U.S. biotech companies where she was responsible for expanding clinical trial portfolios outside of North America. Ms. Bruce holds an M.B.A. from Glasgow Caledonian University where she focused in Executive Leadership and Strategic Management, and is a Member of the Chartered Management Institute.
- Ian Webster
Ian bster自2025年6月起担任临时首席财务官，previoly自2019年起担任财务总监。Bster先生在金融领域拥有超过20年的经验，其中包括在生物制药领域担任超过10年的高级职位。Bster先生的财务经验涵盖财务管理、上市公司报告、审计、税务、并购以及财务规划和分析。在2019年加入之前，他曾于2013年至2019年在专业制药公司Kyowa Kirin International plc担任集团财务总监。Bster先生曾于2002年至2013年在全球会计师事务所普华永道会计师事务所担任高级经理，在英国和加拿大从事审计和交易服务业务。Bster先生是一名特许会计师（苏格兰特许会计师协会），并获得华威大学会计和金融学士学位（荣誉）。
Ian Webster has served as Interim Chief Financial Officer since June 2025 and previoly served as Director of Finance since 2019. Mr. bster has over 20 years of experience in finance, including over 10 years in senior positions within the biopharmaceutical sector. Mr. bster's finance experience spans financial management, listed company reporting, audit, tax, M&A, and financial planning and analysis. Prior to joining in 2019, he served as Group Financial Controller at Kyowa Kirin International plc, a specialty pharmaceutical company from 2013 to 2019. Mr. bster was a senior manager at PricewaterhoeCoopers LLP, a global accounting firm, from 2002 to 2013 working in both the audit and transaction services practices in the U.K. and Canada. Mr. bster is a chartered accountant (Institute of Chartered Accountants of Scotland) and received a BSc (Hons) in Accounting and Finance from the University of Warwick.- Ian bster自2025年6月起担任临时首席财务官，previoly自2019年起担任财务总监。Bster先生在金融领域拥有超过20年的经验，其中包括在生物制药领域担任超过10年的高级职位。Bster先生的财务经验涵盖财务管理、上市公司报告、审计、税务、并购以及财务规划和分析。在2019年加入之前，他曾于2013年至2019年在专业制药公司Kyowa Kirin International plc担任集团财务总监。Bster先生曾于2002年至2013年在全球会计师事务所普华永道会计师事务所担任高级经理，在英国和加拿大从事审计和交易服务业务。Bster先生是一名特许会计师（苏格兰特许会计师协会），并获得华威大学会计和金融学士学位（荣誉）。
- Ian Webster has served as Interim Chief Financial Officer since June 2025 and previoly served as Director of Finance since 2019. Mr. bster has over 20 years of experience in finance, including over 10 years in senior positions within the biopharmaceutical sector. Mr. bster's finance experience spans financial management, listed company reporting, audit, tax, M&A, and financial planning and analysis. Prior to joining in 2019, he served as Group Financial Controller at Kyowa Kirin International plc, a specialty pharmaceutical company from 2013 to 2019. Mr. bster was a senior manager at PricewaterhoeCoopers LLP, a global accounting firm, from 2002 to 2013 working in both the audit and transaction services practices in the U.K. and Canada. Mr. bster is a chartered accountant (Institute of Chartered Accountants of Scotland) and received a BSc (Hons) in Accounting and Finance from the University of Warwick.